Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning
Standard
Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. / Andersen, Rikke; Donia, Marco; Westergaard, Marie Christine Wulff; Pedersen, Magnus; Hansen, Morten; Svane, Inge Marie.
I: Human Vaccines & Immunotherapeutics, Bind 11, Nr. 12, 2015, s. 2790-5.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
AU - Andersen, Rikke
AU - Donia, Marco
AU - Westergaard, Marie Christine Wulff
AU - Pedersen, Magnus
AU - Hansen, Morten
AU - Svane, Inge Marie
PY - 2015
Y1 - 2015
N2 - Personalized cancer immunotherapy based on infusion of T cells holds the promise to specifically target a patient's individual tumor. Accumulating evidence indicates that the T cells mediating these tumor regressions after cancer immunotherapies may primarily target patient-specific mutations expressed by the patients' tumors and that the presence of these "neo-antigen" specific T-cells may be related to a high number of mutations in the tumor. In melanoma, treatment with autologous tumor-infiltrating lymphocytes (TILs) can mediate durable complete responses. Previous trials investigating TIL therapy in solid tumors other than melanoma have shown limited success, however none of these early trials used current preparative chemotherapy regimens, and the methods for in vitro lymphocyte expansion have changed considerably. New advances and understandings in T cell based immunotherapies have stimulated the interest in developing this approach for other indications. Here, we summarize the early clinical data in the field of adoptive cell transfer therapy (ACT) using tumor-infiltrating lymphocytes for patients with renal cell carcinoma (RCC) and ovarian cancer (OC). In addition we describe the major advances in the characterization and application of TIL therapy for patients with RCC and OC.
AB - Personalized cancer immunotherapy based on infusion of T cells holds the promise to specifically target a patient's individual tumor. Accumulating evidence indicates that the T cells mediating these tumor regressions after cancer immunotherapies may primarily target patient-specific mutations expressed by the patients' tumors and that the presence of these "neo-antigen" specific T-cells may be related to a high number of mutations in the tumor. In melanoma, treatment with autologous tumor-infiltrating lymphocytes (TILs) can mediate durable complete responses. Previous trials investigating TIL therapy in solid tumors other than melanoma have shown limited success, however none of these early trials used current preparative chemotherapy regimens, and the methods for in vitro lymphocyte expansion have changed considerably. New advances and understandings in T cell based immunotherapies have stimulated the interest in developing this approach for other indications. Here, we summarize the early clinical data in the field of adoptive cell transfer therapy (ACT) using tumor-infiltrating lymphocytes for patients with renal cell carcinoma (RCC) and ovarian cancer (OC). In addition we describe the major advances in the characterization and application of TIL therapy for patients with RCC and OC.
U2 - 10.1080/21645515.2015.1075106
DO - 10.1080/21645515.2015.1075106
M3 - Comment/debate
C2 - 26308285
VL - 11
SP - 2790
EP - 2795
JO - Human Vaccines & Immunotherapeutics
JF - Human Vaccines & Immunotherapeutics
SN - 2164-5515
IS - 12
ER -
ID: 162855039